NASDAQ:LXEO Lexeo Therapeutics (LXEO) Stock Price, News & Analysis $11.50 -0.29 (-2.46%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$11.36▼$12.0550-Day Range$11.09▼$18.7652-Week Range$9.00▼$22.33Volume299,540 shsAverage Volume479,737 shsMarket Capitalization$378.81 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Lexeo Therapeutics alerts: Email Address Lexeo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside91.3% Upside$22.00 Price TargetShort InterestHealthy3.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 3 Articles This WeekInsider TradingSelling Shares$444,988 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsMedical Sector547th out of 930 stocksBiological Products, Except Diagnostic Industry86th out of 154 stocks 3.6 Analyst's Opinion Consensus RatingLexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Lexeo Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.88% of the float of Lexeo Therapeutics has been sold short.Short Interest Ratio / Days to CoverLexeo Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexeo Therapeutics has recently increased by 8.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexeo Therapeutics does not currently pay a dividend.Dividend GrowthLexeo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXEO. Previous Next 2.5 News and Social Media Coverage News SentimentLexeo Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lexeo Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LXEO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $444,988.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Lexeo Therapeutics is held by insiders.Percentage Held by Institutions60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lexeo Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lexeo Therapeutics are expected to remain at ($2.65) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexeo Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexeo Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexeo Therapeutics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexeo Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. About Lexeo Therapeutics Stock (NASDAQ:LXEO)Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Read More LXEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXEO Stock News HeadlinesJuly 13, 2024 | insidertrades.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 26,969 SharesJuly 26 at 2:20 AM | americanbankingnews.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by AnalystsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 19, 2024 | markets.businessinsider.comPromising Interim Clinical Trial Results Bolster Confidence in Lexeo Therapeutics’ Gene Therapy PotentialJuly 19, 2024 | markets.businessinsider.comLexeo Down Despite Upbeat Rare Disease Gene Therapy DataJuly 19, 2024 | americanbankingnews.comLexeo Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.59) Per Share, Leerink Partnrs Forecasts (NASDAQ:LXEO)July 17, 2024 | americanbankingnews.comLexeo Therapeutics (NASDAQ:LXEO) Given Buy Rating at HC WainwrightJuly 15, 2024 | globenewswire.comLexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 8, 2024 | globenewswire.comLexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of DirectorsMay 9, 2024 | globenewswire.comLexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational HighlightsMay 7, 2024 | globenewswire.comLexeo Therapeutics to Participate in Upcoming Investor ConferencesApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy AdvancementsApril 24, 2024 | uk.investing.comLexeo Therapeutics secures rights to advance gene therapyApril 22, 2024 | finance.yahoo.comLexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyApril 16, 2024 | marketwatch.comLexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia CardiomyopathyApril 16, 2024 | markets.businessinsider.comLexeo's LX2006 Gene Therapy Gets FDA Fast Track Designation; Stock Up In Pre-marketApril 16, 2024 | finance.yahoo.comLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia CardiomyopathySee More Headlines Receive LXEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/27/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LXEO Previous SymbolNASDAQ:LXEO CUSIPN/A CIK1907108 Webwww.lexeotx.com Phone212-547-9879FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$28.00 Low Stock Price Target$19.00 Potential Upside/Downside+91.3%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($22.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-155.79% Return on Assets-51.08% Debt Debt-to-Equity Ratio0.01 Current Ratio9.16 Quick Ratio9.16 Sales & Book Value Annual Sales$650,000.00 Price / Sales582.78 Cash FlowN/A Price / Cash FlowN/A Book Value$4.26 per share Price / Book2.70Miscellaneous Outstanding Shares32,940,000Free Float31,462,000Market Cap$378.81 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. R. Nolan Townsend (Age 43)CEO & Director Comp: $864.34kDr. Eric Adler M.D. (Age 50)Chief Medical Officer & Head of Research Comp: $623.4kMs. Jenny R. Robertson (Age 49)Chief Business & Legal Officer Comp: $617.9kDr. Ronald G. Crystal M.D.Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory BoardDr. Paul B. McCormac Ph.D. (Age 54)Chief Technical Officer Comp: $471.73kDr. Jordan Shin M.D.Ph.D., Senior Vice President of Clinical Development & Translational Science, CardiologyDr. Jordan S. Dubow M.D. (Age 45)Head of CNS Clinical Development Dr. Sandi See Tai M.D. (Age 53)Chief Development Officer Mr. Ryan McHenryVP & Corporate ControllerMore ExecutivesKey CompetitorsVir BiotechnologyNASDAQ:VIRSana BiotechnologyNASDAQ:SANAAutolus TherapeuticsNASDAQ:AUTLRelay TherapeuticsNASDAQ:RLAYCullinan TherapeuticsNASDAQ:CGEMView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 3,483 shares on 7/26/2024Ownership: 0.097%Richard Nolan TownsendSold 26,969 sharesTotal: $444,988.50 ($16.50/share)Artal Group S.A.Bought 198,281 shares on 5/17/2024Ownership: 2.434%RA Capital Management L.P.Bought 660,938 shares on 5/17/2024Ownership: 2.006%Janus Henderson Group PLCBought 210,047 shares on 5/16/2024Ownership: 7.713%View All Insider TransactionsView All Institutional Transactions LXEO Stock Analysis - Frequently Asked Questions How have LXEO shares performed this year? Lexeo Therapeutics' stock was trading at $13.42 at the beginning of 2024. Since then, LXEO shares have decreased by 14.3% and is now trading at $11.50. View the best growth stocks for 2024 here. How were Lexeo Therapeutics' earnings last quarter? Lexeo Therapeutics, Inc. (NASDAQ:LXEO) posted its earnings results on Thursday, May, 9th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.01. When did Lexeo Therapeutics IPO? Lexeo Therapeutics (LXEO) raised $100 million in an IPO on Friday, November 3rd 2023. The company issued 9,090,910 shares at $11.00 per share. Who are Lexeo Therapeutics' major shareholders? Lexeo Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.10%). Insiders that own company stock include Fund Vi LP Omega and Richard Nolan Townsend. View institutional ownership trends. How do I buy shares of Lexeo Therapeutics? Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LXEO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
